Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment

Final results of the Phase I study of acalabrutinib plus STAT3 inhibitor in patients with R/R DLBCL awere reported. Danvatirsen 200 mg intravenous infusion was administered in combination with oral acalabrutinib 100 mg twice daily until progressive disease or unacceptable toxicity.